Physician profile
Wonhee Lee
NPI 1407338585
$13,406.76
in general payments reported to CMS, 2019-2025
45 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,796 · 2022: $2,604 · 2023: $2,533 · 2024: $2,319 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,998 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,998.42 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.55 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $1,131.03 | 2021-2023 | |
| Lilly USA, LLC | $1,120.45 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $919.28 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $891.40 | 2021-2025 | Evenity, Prolia, Repatha |
| Aimmune Therapeutics, INC. | $831.67 | 2024-2025 | Zenpep |
| Fresenius USA Marketing, INC. | $632.08 | 2021-2025 | Velphoro, Korsuva, Velphoro |
| Pfizer INC. | $590.99 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $553.30 | 2021-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.28 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $439.12 | 2021-2025 | |
| Astellas Pharma US INC | $437.12 | 2021-2023 | Veozah, Myrbetriq |
| Travere Therapeutics, INC. | $419.80 | 2022-2025 | |
| Ardelyx, INC. | $401.02 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Glaxosmithkline, LLC. | $377.44 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonhee Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.